MannKind

September 05, 2018

United finds a seventh way to serve up treprostinil

Extending a pulmonary hypertension drug’s lifecycle could help battle generic erosion, but investors might have been looking for a more transformative deal.

United finds a seventh way to serve up treprostinil

After Alnylam’s solo maiden launch, here comes the tricky bit

The big launches of 2014 – where are they now?

Mid-cap biopharma stocks pick up in the first quarter

Acorda up, but patent battle looms

Snippet roundup: Christmas comes early for Pfizer’s bankers and Mannkind

Oral insulin could be fools’ gold

Slow Praluent launch another canary in pharma’s coalmine

Fighting over Mannkind’s corpse

Bayer: We wish Mr Brandicourt well

Shifts in consensus leave Novartis's pipeline both a winner and a loser

Latest Reports

Vantage Pharma, Biotech and Medtech 2018 in Review

Vantage 2019 Preview

Editor's Picks

Array-size deals don’t come around too often

Takeda casts doubt on the remaining approach to amyloidosis

EHA 2019 – Global Blood faces sickle cell questions

Liquid biopsies: the future of cancer diagnosis?

Time to restock big pharma’s leaking pipeline